当前位置: 首页 >> 检索结果
282. Targetable Mutations in BRAF V600E-Negative Hairy-Cell Leukemia.
作者: Alessia Santi.;Alessandra Venanzi.;Alessandra Pucciarini.;Gianluca Schiavoni.;Marta Naccari.;Elisa Albi.;Lorenzo De Paoli.;Tamara Intermesoli.;Stefano Lazzi.;Esmeralda Conte.;Alessandro Mancini.;Brunangelo Falini.;Alessandro Gozzetti.;Gianna M D'Elia.;Angelo Genua.;Enrico Tiacci.
来源: N Engl J Med. 2025年392卷14期1451-1452页 288. Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.
作者: Jana K McHugh.;Elizabeth K Bancroft.;Edward Saunders.;Mark N Brook.;Eva McGrowder.;Sarah Wakerell.;Denzil James.;Reshma Rageevakumar.;Barbara Benton.;Natalie Taylor.;Kathryn Myhill.;Matthew Hogben.;Netty Kinsella.;Aslam A Sohaib.;Declan Cahill.;Stephen Hazell.;Samuel J Withey.;Naami Mcaddy.;Elizabeth C Page.;Andrea Osborne.;Sarah Benafif.;Ann-Britt Jones.;Dhruv Patel.;Dean Y Huang.;Kaljit Kaur.;Bradley Russell.;Ray Nicholson.;Fionnuala Croft.;Justyna Sobczak.;Claire McNally.;Fiona Mutch.;Samantha Bennett.;Lenita Kingston.;Questa Karlsson.;Tokhir Dadaev.;Sibel Saya.;Susan Merson.;Angela Wood.;Nening Dennis.;Nafisa Hussain.;Alison Thwaites.;Syed Hussain.;Imran Rafi.;Michelle Ferris.;Pardeep Kumar.;Nicholas D James.;Nora Pashayan.;Zsofia Kote-Jarai.;Rosalind A Eeles.; .
来源: N Engl J Med. 2025年392卷14期1406-1417页
The incidence of prostate cancer is increasing. Screening with an assay of prostate-specific antigen (PSA) has a high rate for false positive results. Genomewide association studies have identified common germline variants in persons with prostate cancer, which can be used to calculate a polygenic risk score associated with risk of prostate cancer.
290. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.
作者: Robert J Fox.;Amit Bar-Or.;Anthony Traboulsee.;Celia Oreja-Guevara.;Gavin Giovannoni.;Patrick Vermersch.;Sana Syed.;Ye Li.;Wendy S Vargas.;Timothy J Turner.;Erik Wallstroem.;Daniel S Reich.; .
来源: N Engl J Med. 2025年392卷19期1883-1892页
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple sclerosis have limited effects on disability accrual unrelated to relapses, which is thought to be partially caused by chronic, nonresolving neuroinflammation within the central nervous system. Tolebrutinib is an oral, brain-penetrant Bruton's tyrosine kinase inhibitor that targets myeloid cells (including microglia) and B cells in both the periphery and central nervous system. There are no approved treatments for nonrelapsing secondary progressive multiple sclerosis.
291. Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
作者: Jiwon Oh.;Douglas L Arnold.;Bruce A C Cree.;Carolina Ionete.;Ho Jin Kim.;Maria Pia Sormani.;Sana Syed.;Yixin Chen.;Christina R Maxwell.;Patrick Benoit.;Timothy J Turner.;Erik Wallstroem.;Heinz Wiendl.; .
来源: N Engl J Med. 2025年392卷19期1893-1904页
Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton's tyrosine kinase inhibitor that modulates peripheral inflammation and persistent immune activation within the central nervous system, including disease-associated microglia and B cells. More data are needed on its efficacy and safety in treating relapsing multiple sclerosis.
292. A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
作者: Richard J Nowak.;Michael Benatar.;Emma Ciafaloni.;James F Howard.;M Isabel Leite.;Kimiaki Utsugisawa.;John Vissing.;Mikhail Rojavin.;Qing Li.;Fengming Tang.;Yanping Wu.;Nishi Rampal.;Sue Cheng.; .
来源: N Engl J Med. 2025年392卷23期2309-2320页
Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to disease pathogenesis.
299. A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.
作者: Daniel Blockmans.;Sara K Penn.;Arathi R Setty.;Wolfgang A Schmidt.;Andrea Rubbert-Roth.;Ellen M Hauge.;Helen I Keen.;Tomonori Ishii.;Nader Khalidi.;Christian Dejaco.;Maria C Cid.;Bernhard Hellmich.;Meng Liu.;Weihan Zhao.;Ivan Lagunes.;Ana B Romero.;Peter K Wung.;Peter A Merkel.; .
来源: N Engl J Med. 2025年392卷20期2013-2024页
Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib - a selective Janus kinase (JAK) inhibitor that blocks the signaling of several cytokines, including interleukin-6 and interferon-γ - are unknown in patients with giant-cell arteritis.
|